Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
1.960
-0.060 (-2.97%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types.
It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.
The company was founded in 2003 and is headquartered in Houston, Texas.
Alaunos Therapeutics, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Dale Hogue |
Contact Details
Address: 2617 Bissonnet Street, Suite 225 Houston, Texas 77005 United States | |
| Phone | 346 355 4099 |
| Website | alaunos.com |
Stock Details
| Ticker Symbol | TCRT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001107421 |
| CUSIP Number | 98973P101 |
| ISIN Number | US98973P2002 |
| Employer ID | 84-1475642 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dale Curtis Hogue Jr. | Interim Chief Executive Officer and Director |
| Melinda Lackey | Senior Vice President of Legal, Administration and Secretary |
| Michael Wong | Vice President of Finance and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 10, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Jul 17, 2024 | 8-K/A | [Amend] Current report |
| Jul 17, 2024 | 8-K/A | [Amend] Current report |
| Jul 16, 2024 | 8-K | Current Report |
| Jul 16, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 12, 2024 | 8-K | Current Report |